Genprex Secures Key Reqorsa® Gene Therapy Patents in Japan and Europe
GNPX is trading near its 52-week low of $1.71 (9.4% above the low) on light trading volume (0.3× avg).
Summary
Genprex announced new patent grants in Japan and Europe for its Reqorsa® Gene Therapy, strengthening its intellectual property for cancer treatment combinations and providing an update on its Acclaim-3 clinical trial.
Key Events · Product Development and Regulatory · GNPX
-
Japanese Patent Grant for Reqorsa®
The Japanese Patent Office issued a favorable Appeal Decision to grant a patent claiming the use of Reqorsa® Gene Therapy in combination with PD-L1 antibodies to treat cancer.
-
European Patent Grant for Reqorsa®
The European Patent Office has issued a Decision to Grant relating to a patent for the combination of REQORSA and PD-1 antibodies to treat cancer.
-
Strengthened IP Portfolio
These new patents in key markets strengthen Genprex's intellectual property, providing further protection for various therapeutic combinations, including the Acclaim-3 clinical trial for small cell lung cancer.
-
Acclaim-3 Clinical Trial Progress
The Phase 1 dose escalation portion of the Acclaim-3 clinical trial (REQORSA with Tecentriq® for small cell lung cancer) was successfully completed, showing REQORSA was generally well tolerated. The Phase 2 expansion is expected to enroll approximately 50 patients, with interim analysis for the first 25 patients anticipated in the second half of 2026.
Analysis · GNPX · Life Sciences
Genprex, a clinical-stage biotechnology company, has significantly strengthened its intellectual property portfolio by securing new patent grants in Japan and Europe for its lead oncology candidate, Reqorsa® Gene Therapy. These patents protect Reqorsa's use in combination with PD-L1 and PD-1 antibodies to treat cancer, including its application in the ongoing Acclaim-3 clinical trial for small cell lung cancer. The successful completion of Phase 1 of the Acclaim-3 trial, with Reqorsa being well-tolerated, and the progression to Phase 2, provides further positive momentum for the company's core asset. This IP expansion in major markets is crucial for future commercialization and enhances the long-term value of the company's therapeutic pipeline.
At the time of this filing, GNPX was trading at $1.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.1M. The 52-week trading range was $1.71 to $55.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.